Company / Current Assets
BioMarin Pharmaceutical Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$4.0B
FY2025
5-year range
$2.3B / $4.0B
FY2021-FY2025
Trend
+22.3%
vs FY2024
Sector context
#22 of 213
Health Care
What the data says
Among 213 Health Care companies, BioMarin Pharmaceutical is in the top 10% for current assets. Current Assets has increased for 4 consecutive years, from $2.3B in FY2021 to $4.0B in FY2025.
Based on SEC 10-K filings.
$4.0B in FY2025 with a 5-year CAGR of +11.0%. Top quartile in the Health Care sector.
Improved from $3.0B to $4.0B over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +12.8%
- 5-Year CAGR
- +11.0%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 213This company $4.0B Sector average $2.5B
▼
+56.7% above sector average
Key checks
Key Insights
- BioMarin Pharmaceutical's current assets has grown for 4 consecutive years.
- 5-year CAGR of +11.0%, indicating consistent growth.
- In FY2025, current assets increased 22.3% year-over-year.
- Ranks #22 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.0B | +22.3% |
| FY2024 | $3.2B | +9.3% |
| FY2023 | $3.0B | +7.4% |
| FY2022 | $2.8B | +21.0% |
| FY2021 | $2.3B | -2.9% |
| FY2020 | $2.3B | +20.6% |
| FY2019 | $1.9B | -5.5% |
| FY2018 | $2.1B | -6.8% |
| FY2017 | $2.2B | +55.2% |
| FY2016 | $1.4B | +30.5% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026